Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial (WAKE-UP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Denmark,Germany,Spain,Belgium,France,United Kingdom,Germany,Germany,Belgium,United Kingdom
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2011-12-01
End date: 2017-11-30
Duration (months): 72.0
Total project cost (EUR): 15899832.65
EU funding (EUR): 11599987.0
Participants: 13
Project status: CLOSED

WAKE-UP is an investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial designed to test efficacy and safety of MRI-based intravenous thrombolysis in patients with wake-up stroke. Every year 1.5 million patients suffer a stroke in the EU. Up to 20% of stroke patients wake up with stroke symptoms. Currently these patients are excluded from thrombolysis which is the only approved specific treatment available for acute stroke. However, recently the potential of MRI to identify patients likely to be within a time-window for thrombolysis (≤4.5 hours) was demonstrated. WAKE-UP will use a specific MRI pattern, i.e. the mismatch between a visible lesion on diffusion weighted imaging (DWI) and a normal fluid attenuated inversion recovery (FLAIR) image, to randomise patients waking up with stroke symptoms to either treatment with Alteplase or placebo. The primary endpoint will be favourable outcome at 3 months. A total of 800 patients will be enrolled in 40 centres in six EU countries. Additional MRI information such as vessel occlusion or perfusion lesion will not be used for enrolment but will be studied as possible modifiers of the response to thrombolysis. Software will be developed to facilitate the processing and analysis of multiparametric stroke MRI and to assist the integration of modern stroke imaging into acute treatment decisions. The trial will be accompanied by activities increasing the awareness for acute stroke in the public and results will be disseminated within the scientific community as well as within the public. WAKE-UP is aimed to promote a paradigm-change in acute stroke treatment, and to provide effective treatment to a large new group of patients. The results of WAKE-UP are expected to change guidelines of acute stroke management and clinical practice. WAKE-UP will help to reduce the burden of stroke related disability in the EU.

Keywords: acute ischemic stroke,wake-up stroke,thrombolysis,recombinant tissue plasminogen activator,rtpa,alteplase,placebo,mri,diffusion weighted imaging,fluid attenuated inversion recovery,rct
High-throughput peptidomics and transcriptomics of animal venoms for discovery of novel therapeutic peptides and innovative drug development (VENOMICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,France,Spain,Portugal,France,France,Belgium,Belgium,Denmark
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2011-11-01
End date: 2015-10-31
Duration (months): 48.0
Total project cost (EUR): 9360275.25
EU funding (EUR): 5998786.65
Participants: 10
Project status: CLOSED

Animal venoms are complex cocktails of peptides that have enormous potential as novel therapeutic leads. Replicating in vitro the diversity of venoms by generating large synthetic combinatorial peptide libraries will solve the challenge of working with limited amounts of natural products and permit high-throughput investigation of their pharmacology. A new investigation paradigm associating transcriptomics and proteomics is the only way to achieve this goal and to address the complexity of this unexplored 40,000,000 peptide resource. The vision of the VENOMICS project is to develop, integrate and implement cutting-edge and innovative technologies in a high-throughput approach to investigate the enormous structural and pharmacological diversity of venom peptides. We will use the largest venom and venom gland collection in the world to generate a comprehensive sequence database of bioactive peptides, and produce a 10,000 reticulated peptide bank to be used in drug discovery efforts and development of novel therapeutics. A 1000-fold improvement in throughput over the current situation (1 to 2 candidates generated per year) is reasonably foreseen. Implementation of the project will require both improvements and the integration of exisiting technologies in a high-throughput workflow comprising venom and tissue sourcing, mass spectrometry-based automated de novo peptide sequencing, transcriptomics of venom gland-derived RNA or cDNA/EST libraries, bioinformatics, implementation of a sequence database, and highly parallel synthetic or recombinant production including peptide refolding. The last step will be the validation of the approach in functional assays targeting specific pathologies. VENOMICS is a high-impact project with societal (new drugs against life threatening diseases), scientific and technological (filling the drug discovery pipeline), political (European leadership in the field) and economic (new opportunities for the biologics market) benefits.

Keywords: peptides,venom,therapeutics,drugs,proteomics,transcriptomics,pharmacology,recombinant production,peptide synthesis,biologics
DRIVERS: Addressing the strategic Determinants to Reduce health Inequality Via 1) Early childhood development, 2) Realising fair employment, and 3) Social protection (DRIVERS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Belgium,United Kingdom,Germany,Sweden
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2012-01-01
End date: 2015-02-28
Duration (months): 38.0
Total project cost (EUR): 3526534.88
EU funding (EUR): 2799593.68
Participants: 6
Project status: CLOSED

There is evidence that social gradients in health exist both between and within countries. This research proposal will build on the recommendations of the Commission on Social Determinants of Health (CSDH) and the Marmot Review of Health Inequalities, as well as on two European reviews commissioned by the EC and WHO Europe that are currently underway. It will focus on three of the key drivers to reduce health inequities: * early childhood development; * employment and the work environment; * income, welfare and social protection. The research will review evidence and the methods to assess the impact of policies and programmes in these three areas relating to health inequities, develop new methods and evidence, and provide policy recommendations and advocacy guidance. The three main objectives are: 1) identifying and filling key gaps in knowledge about policies driving these three social determinants, 2) analysing methods which have been applied to assess these effects, improving or developing new methods and applying and testing them in case studies across Europe. 3) assessing how the research findings are applicable to real-life situations and stakeholders, and providing advocacy guidance and policy recommendations to reduce health inequalities. The research will be undertaken by a consortium of research bodies - UCL, Dusseldorf University and the Swedish Centre for Health Equity Studies- in partnership with organisations representing the public health sector, civil society and business (EuroHealthNet, EAPN, Eurochild and BiTC). Partners will contribute to case studies, testing methodologies and applying participatory approaches to ensure that outcomes are grounded in socioeconomic realities. EuroHealthNet, with expertise in coordinating EU projects and in EU policy issues will manage the project and lead on the advocacy research and dissemination. Research outcomes will contribute to meeting the EU 2020 targets and related flagship initiatives.

Keywords: social determinants of health,health inequalities,methodologies,policy and programme evaluation,early childhood development,employment conditions,social protection,human rights,participation.
European Multicentre Tics in Children Studies (EMTICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Italy,United Kingdom,Germany,Germany,Greece,Israel,United Kingdom,Belgium,Italy,Germany,Germany,Hungary,Spain,Switzerland,Spain,Denmark,Germany,Germany,United Kingdom,Netherlands,United Kingdom
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2011-12-01
End date: 2018-05-31
Duration (months): 78.0
Total project cost (EUR): 7891221.99
EU funding (EUR): 5966392.0
Participants: 30
Project status: CLOSED

This project will undertake pre-clinical and cohort studies that address susceptibility factors for paediatric and adolescent tic disorders, with a particular focus on comorbid obsessive-compulsive symptomatology, from clinical, epidemiological, genetic, microbiological and immunological angles. EMTICS aims to elucidate the complex aetiology of the onset and clinical course of chronic tic disorders and associated obsessive-compulsive symptoms, through disentangling the interplay between environmental factors and genetic background; translate research findings into clinical applications by developing disease prediction models and investigation of a treatment strategy; and will establish a Pan-European infrastructure for the study of tic disorders. We hypothesise that the onset and/or exacerbation of tic and comorbid obsessive-compulsive disorders is associated with increased preceding occurrence of Group A beta-haemolytic Streptococcus (GAS) infections of specific molecular subtypes, and that this association is based on genetic susceptibility factors and mediated through immunological mechanisms related to psychosocial stress and immunological factors in host and GAS strains. Large-scale cohort studies will involve affected patients and at-risk first-degree relatives within an integrated, multidisciplinary research strategy. Treatment effects of active surveillance and standardized antibiotic treatment of GAS colonisation, thus addressing one of the main environmental factors involved (GAS infections) will be evaluated. Our approach will result in the identification of genetic and environmental susceptibility factors and will greatly contribute to a better understanding of the underlying mechanisms of tic disorders, with a focus on elucidating the role of autoimmunity. Our consortium brings together the highest expertise in the field of tic disorders across Europe in academia and industry, including a number of SMEs and a professional management company.

Keywords: tourette syndrome,obsessive-compulsive disorder,group a beta-haemolytic streptococcus,cortisol,psychosocial stress,genome-wide association,gene expression,antibiotics,autoimmunity
Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population (EURHYTHDIA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Germany,Switzerland,Finland,Belgium,United Kingdom,Netherlands,France,United Kingdom,Germany,Italy,Austria,Germany
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2011-10-01
End date: 2017-06-30
Duration (months): 69.0
Total project cost (EUR): 7696424.92
EU funding (EUR): 5997889.45
Participants: 17
Project status: CLOSED

Modern lifestyle has dramatically changed the daily rhythms of life. Physical activity, diet and light exposure are no longer restricted to daytime hours, as technical and economical de-mands fuel the necessity to work outside usual working hours. Recent studies show that al-tered light exposure, shifted exercise patterns and untimely food intake following extended active periods into the night disturb the circadian clocks and severely disrupt endocrine and metabolic processes, contributing to an increased risk of type 2 diabetes/obesity. Especially shift workers constituting 20% of the European working population are affected by this prob-lem. Until now only few studies investigating circadian rhythm disturbances in the context of type 2 diabetes/obesity have been conducted in man. Within EuRhythDia a consortium of leading scientists supported by research-intensive SMEs aims to close this gap. The objective of the project is to achieve breakthroughs in the understanding of the causality between inner clock rhythm disturbances and the development of type 2 diabetes/obesity, and to verify whether re-setting the circadian clock through lifestyle interventions (exercise, diet, light exposure and melatonin intake) alters cardiometabolic risk to a clinically relevant degree. The project is based on shift workers as a model and combines genetic, epigenetic, proteomic, metabolomic, physiological, and clinical approaches. The consortium has direct access to well characterised human data incl. individuals predisposed to type 2 diabetes via LUPS co-hort. Additional small interventional and validation cohorts of shift workers and high risk juveniles will be recruited, and supportive animal studies will be conducted. Through the de-velopment of novel diagnostic assays enabling identification of patients at risk and elaboration of targeted prevention guidelines focusing on shift workers and juveniles, EuRhythDia will contribute to a positive impact on European citizens` health.

Keywords: diabetes obesity shift work first degree relatives circadian rhythm disturbances chronotherapeutic lifestyle intervention targeted prevention
Development of antibiofilm coatings for implants (COATIM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Belgium,Belgium,United Kingdom,Slovenia,France,France,Sweden,Germany,Switzerland
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2012-01-01
End date: 2015-12-31
Duration (months): 48.0
Total project cost (EUR): 3888343.65
EU funding (EUR): 2999935.99
Participants: 11
Project status: CLOSED

The aim of the SME-driven COATIM consortium is to tackle the increasing problem of infections due to biofilms, groups of microorganisms that stick together on different surfaces within the human body and escape conventional antibiotic treatment. Biofilms are typically found on medical devices like implants. The most recent generation of implants with open porosity enable fast osseointegration, but also present an increased risk of microbial biofilm-associated infection. Biofilm-associated infections are responsible for 15-25% of implant failure, and necessitate burdensome and costly revision surgery. The latter is estimated to represent a supplementary medical cost of €800m/year in Europe without taking into account the pain and distress of the patients, indicating that any significant reduction of this type of implant failure is highly recommended. Until now, biocidal implant coatings have been developed that are based on either the release of silver ions, which are toxic upon accumulation, or on conventional antibiotics that have poor activity against microorganisms in biofilms. Therefore, COATIM aims to develop the next generation of implant coatings containing novel potent proprietary antibiofilm molecules (ABMs) with inhibitory activity against microbial biofilms. In COATIM, these ABMs are grafted or deposited on small titanium implant substrates, as a model for dental and orthopaedic implants. Next, the ABM-coated implants are evaluated for in vitro and in vivo activity in resisting microbial infection without compromising osseointegration. Finally, the ABM-coating is applied on complex orthopaedic and dental implants, allowing the exploitation of the results by industry. In parallel, the antibiofilm mode of action of the ABMs is unraveled. COATIM contributes to a dynamic and competitive knowledge-based economy, sustainable development, and serves the needs of the SME-intensive medical technology products market in Europe.

Keywords: antifungal,antibacterial,persister,biofilm,coating,dental implant,orthopaedic implant,prevention,curative,osteointegration,in vivo efficacy
Preparedness, Prediction and Prevention of Emerging Zoonotic Viruses with Pandemic Potential using Multidisciplinary Approaches (PREDEMICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Italy,Belgium,France,Switzerland,United Kingdom,France,Germany,Spain,Sweden,Germany,United Kingdom,Italy,Spain
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2011-11-01
End date: 2017-04-30
Duration (months): 66.0
Total project cost (EUR): 15162937.16
EU funding (EUR): 11758352.0
Participants: 20
Project status: CLOSED

The capacity of zoonotic RNA viruses to emerge as major agents of human disease can appear limitless. Current intervention strategies have demonstrated limited success. Rapid, innovative and effective solutions are needed to reduce the apparently accelerating process of zoonotic disease emergence. We will study the following zoonotic viruses with epidemic potential in Europe: influenza virus, hepatitis E virus, viruses of the Japanese encephalitis serocomplex and lyssaviruses. These diverse viruses arise from the main reservoirs and vectors of potentially emerging viral diseases and use the three major routes of transmission: respiratory, faecal-oral and vector borne. Inter-disciplinary studies will generate valuable data on patterns of crossing the species barrier, transmission and disease emergence, including ecological and anthropological factors which determine virus availability and opportunities for exposure and infection. We will unravel the complex biological interactions between the virus and the recipient hosts that drive the viral adaptation and elucidate the factors determining the ability of the viruses to spread to and between humans (including pandemic spread). Furthermore, immune mechanisms of protection and novel prevention strategies will be investigated. Data will be compiled in a unique and freely accessible data-sharing platform to build a framework for analysing the drivers of pathogen emergence. Modelling, building on the analysis of key data, will focus on the extent to which pathogen trajectories are predictable and will identify high-risk situations and environments. This will allow improvement of disease surveillance, control, preparedness and intervention. Training in leading European Universities, as well as exchanges of approaches and data sharing with national and international health organizations will strengthen European position in this global challenge.

Keywords: emerging disease,epidemics,pandemics,zoonotic virus,one health,information-sharing platform,training,preparedness,control measures
European clinical study for the application of regenerative heart valves (ESPOIR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Moldova, Republic of,Netherlands,United Kingdom,Italy,France,Switzerland,Belgium,Belgium
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2012-01-01
End date: 2016-12-31
Duration (months): 60.0
Total project cost (EUR): 6645283.72
EU funding (EUR): 5200000.0
Participants: 15
Project status: CLOSED

Acquired and congenital heart disease can necessitate heart valve replacement. However, current heart valve substitutes are not considered ideal as they need anticoagulation, bearing the risk of bleeding when manufactured from non-organic material, or they degenerate when they derive from animals or human tissue donators (homografts) thereby leading to frequent reoperation especially in the young population. An ideal heart valve substitute would overcome these limitations and even have the potential to grow when implanted in pediatric patients. Haverich et al. have developed an implant for heart valves, which is better tolerated than the known alternatives and which has the potential for regeneration by autologous recellularization. Implants derive from donated homografts, which are chemically treated to inactivate potential microorganisms and viruses. The heart valves then are decellularized chemically, so that only connective tissue remains, the matrix of the decellularized heart valve (DHV). DHV has been examined in extensive animal studies, including immunological and toxicological analysis, long term and growth models, all of which have shown that the implant is well tolerated and spontaneously recellularized by the recipient. The proposed ESPOIR project is based on auspicious early clinical results in 45 children and young adults. In order to drive translation of this promising regenerative approach towards practical clinical use and to reduce the burden of congenital heart defects in particular, the ESPOIR consortium will undertake a prospective multi-centre trial to include at least 200 patients from 8 leading European Centres for Congenital Heart Surgery, for robust statistical evaluation of DHV in direct comparison to conventional heart valve substitutes.

Keywords: heart valve replacement,tissue engineering,decellularization,regeneration by recellularization
Next Generation of 2D-Nanomaterials: Enabling Supercapacitor Development (2DNANOCAPS)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Products and process engineering
Countries involved: Ireland,United Kingdom
Call:  (ERC-2011-StG_20101014, 2011)
Start date: 2011-10-01
End date: 2016-09-30
Duration (months): 60.0
Total project cost (EUR): 1501296.0
EU funding (EUR): 1501296.0
Participants: 2
Project status: CLOSED

Climate change and the decreasing availability of fossil fuels require society to move towards sustainable and renewable resources. 2DNanoCaps will focus on electrochemical energy storage, specifically supercapacitors. In terms of performance supercapacitors fill up the gap between batteries and the classical capacitors. Whereas batteries possess a high energy density but low power density, supercapacitors possess high power density but low energy density. Efforts are currently dedicated to move supercapacitors towards high energy density and high power density performance. Improvements have been achieved in the last few years due to the use of new electrode nanomaterials and the design of new hybrid faradic/capacitive systems. We recognize, however, that we are reaching a newer limit beyond which we will only see small incremental improvements. The main reason for this being the intrinsic difficulty in handling and processing materials at the nano-scale and the lack of communication across different scientific disciplines. I plan to use a multidisciplinary approach, where novel nanomaterials, existing knowledge on nano-scale processing and established expertise in device fabrication and testing will be brought together to focus on creating more efficient supercapacitor technologies. 2DNanoCaps will exploit liquid phase exfoliated two-dimensional nanomaterials such as transition metal oxides, layered metal chalcogenides and graphene as electrode materials. Electrodes will be ultra-thin (capacitance and thickness of the electrodes are inversely proportional), conductive, with high dielectric constants. Intercalation of ions between the assembled 2D flakes will be also achievable, providing pseudo-capacitance. The research here proposed will be initially based on fundamental laboratory studies, recognising that this holds the key to achieving step-change in supercapacitors, but also includes scaling-up and hybridisation as final objectives.

Keywords: two-dimensional nanomaterials,supercapacitors,liquid-phase exfoliation,upscaling,transition metal chalcogenides,transition metal oxides